LexDanaLexDanabeta
Inventor

Peter John Murray

Inventor
London, GB

Overview

39→
Patents
2003–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 39 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
C07DHeterocyclic compounds32%
A61KPreparations for medical, dental or toiletry purposes24%
G06FElectric digital data processing4%
G11CStatic stores4%
A61QSpecific use of cosmetics or similar toiletry preparations2%
C07CAcyclic or carbocyclic compounds2%
Y10TTechnical subjects covered by former us classification2%
PatentTitleYear
10,858,345Process for preparing a compound useful to treat mycoses202010,662,179Process for preparing a compound useful to treat mycoses202010,626,126Compounds202010,472,3755,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative201910,450,304Compound useful to treat mycoses201910,358,445Respiratory formulations and compounds for use therein201910,344,022Compound useful to treat mycoses201910,273,2495,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative201910,189,8635,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives201910,144,721P38 MAP kinase inhibitors201810,106,531Compound useful to treat mycoses201810,035,8105,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative201810,028,959Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors201810,000,471Pyrazole P38 map kinase inhibitors20189,926,335'5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative'20189,834,560Compounds20179,771,354'Pyrazole p38 map kinase inhibitors'20179,732,098'5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative'20179,701,670'Pyrazolyl-ureas as kinase inhibitors'20179,637,494'Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors'20179,340,545'Quinazolin-4 (3H)—one derivatives used as P13 kinase inhibitors'20169,321,773'Compounds'20169,260,410'P38 MAP kinase inhibitors'20169,249,125'Pyrazole derivatives as p38 MAP inhibitors'20169,242,960'P38MAP kinase inhibitors'20169,024,041'P38 MAP kinase inhibitors'20158,975,285'P38 MAP kinase inhibitors'20158,933,228'Respiratory formulations and compounds for use therein'20158,741,909'PI3 kinase inhibitors'20148,642,773'P38MAP kinase inhibitor'20148,618,140'P38 MAP kinase inhibitors'20138,299,073'P38 MAP kinase inhibitors'20128,299,074'P38 MAP kinase inhibitors'20128,293,771'p38 MAP kinase inhibitors'20128,293,748'p38 MAP kinase inhibitors'20128,158,622'Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase'20127,405,210'Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase'20086,797,731'Resorcinol derivatives'20046,541,473'Resorcinol derivatives'2003

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2003–2004Based in Birmingham, GB· patent location history
2008–2012Based in Oxford, GB· patent location history
2012–2019Patents assigned to RESPIVERT LTD (23)· patent assignee history
2012–2018Patents assigned to MURRAY PETER JOHN (13)· patent assignee history
2012–2018Patents assigned to ITO KAZUHIRO (10)· patent assignee history
2012–2018Patents assigned to ONIONS STUART THOMAS (10)· patent assignee history
2012–2020Based in London, GB· patent location history
2017–2020Patents assigned to PULMOCIDE LTD (12)· patent assignee history
2017–2018Based in Cheltenham, GB· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
RESPIVERT LTD232012–2019
MURRAY PETER JOHNself132012–2018
PULMOCIDE LTD122017–2020
ITO KAZUHIRO102012–2018
ONIONS STUART THOMAS102012–2018
Locations
LocationPatentsSpan
London, GB292012–2020
Cheltenham, GB62017–2018
Oxford, GB22008–2012
Birmingham, GB22003–2004